Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985790489> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1985790489 endingPage "261" @default.
- W1985790489 startingPage "260" @default.
- W1985790489 abstract "Docetaxel is a new taxoid drug with good activity against human breast cancer cells in vitro; a number of partial and minor responses have been obtained during phase I studies in patients with advanced breast cancer. In phase II trials, first-line use of docetaxel has produced an overall response rate (OR) of up to 73%. In addition, docetaxel has shown good activity when given as second-line therapy (OR 38%), particularly in patients with disease refractory to anthracyclines (OR 55%). Indeed, the high response rate in this latter group of patients clearly warrants further investigation of docetaxel in this setting. Neutropenia is the major dose-limiting toxicity of docetaxel, but other haematological effects are rare. Hypersensitivity and cutaneous reactions are ameliorated by premedication with corticosteroids and histamine antagonists; fluid retention may improve with longer use of prophylactic premedication. Docetaxel is mildly emetogenic, but no other premedication is necessary. In summary, docetaxel is an active new drug in the treatment of advanced breast cancer. Its role in the management of early stage disease awaits the results of prospective randomised trials." @default.
- W1985790489 created "2016-06-24" @default.
- W1985790489 creator A5017924783 @default.
- W1985790489 creator A5018483475 @default.
- W1985790489 creator A5019240414 @default.
- W1985790489 creator A5020754357 @default.
- W1985790489 creator A5026179323 @default.
- W1985790489 creator A5027561644 @default.
- W1985790489 creator A5042202815 @default.
- W1985790489 creator A5058774760 @default.
- W1985790489 creator A5067480846 @default.
- W1985790489 creator A5085333105 @default.
- W1985790489 date "2009-09-01" @default.
- W1985790489 modified "2023-10-16" @default.
- W1985790489 title "5003 Phase II study of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: activity and safety results" @default.
- W1985790489 doi "https://doi.org/10.1016/s1359-6349(09)70895-x" @default.
- W1985790489 hasPublicationYear "2009" @default.
- W1985790489 type Work @default.
- W1985790489 sameAs 1985790489 @default.
- W1985790489 citedByCount "0" @default.
- W1985790489 crossrefType "journal-article" @default.
- W1985790489 hasAuthorship W1985790489A5017924783 @default.
- W1985790489 hasAuthorship W1985790489A5018483475 @default.
- W1985790489 hasAuthorship W1985790489A5019240414 @default.
- W1985790489 hasAuthorship W1985790489A5020754357 @default.
- W1985790489 hasAuthorship W1985790489A5026179323 @default.
- W1985790489 hasAuthorship W1985790489A5027561644 @default.
- W1985790489 hasAuthorship W1985790489A5042202815 @default.
- W1985790489 hasAuthorship W1985790489A5058774760 @default.
- W1985790489 hasAuthorship W1985790489A5067480846 @default.
- W1985790489 hasAuthorship W1985790489A5085333105 @default.
- W1985790489 hasConcept C121608353 @default.
- W1985790489 hasConcept C126322002 @default.
- W1985790489 hasConcept C141071460 @default.
- W1985790489 hasConcept C143998085 @default.
- W1985790489 hasConcept C2775930923 @default.
- W1985790489 hasConcept C2776694085 @default.
- W1985790489 hasConcept C2777063308 @default.
- W1985790489 hasConcept C2777292972 @default.
- W1985790489 hasConcept C2778300832 @default.
- W1985790489 hasConcept C2781190966 @default.
- W1985790489 hasConcept C530470458 @default.
- W1985790489 hasConcept C71924100 @default.
- W1985790489 hasConcept C98274493 @default.
- W1985790489 hasConceptScore W1985790489C121608353 @default.
- W1985790489 hasConceptScore W1985790489C126322002 @default.
- W1985790489 hasConceptScore W1985790489C141071460 @default.
- W1985790489 hasConceptScore W1985790489C143998085 @default.
- W1985790489 hasConceptScore W1985790489C2775930923 @default.
- W1985790489 hasConceptScore W1985790489C2776694085 @default.
- W1985790489 hasConceptScore W1985790489C2777063308 @default.
- W1985790489 hasConceptScore W1985790489C2777292972 @default.
- W1985790489 hasConceptScore W1985790489C2778300832 @default.
- W1985790489 hasConceptScore W1985790489C2781190966 @default.
- W1985790489 hasConceptScore W1985790489C530470458 @default.
- W1985790489 hasConceptScore W1985790489C71924100 @default.
- W1985790489 hasConceptScore W1985790489C98274493 @default.
- W1985790489 hasIssue "2" @default.
- W1985790489 hasLocation W19857904891 @default.
- W1985790489 hasOpenAccess W1985790489 @default.
- W1985790489 hasPrimaryLocation W19857904891 @default.
- W1985790489 hasRelatedWork W1992476714 @default.
- W1985790489 hasRelatedWork W2029752720 @default.
- W1985790489 hasRelatedWork W2048754569 @default.
- W1985790489 hasRelatedWork W2117972559 @default.
- W1985790489 hasRelatedWork W2148493940 @default.
- W1985790489 hasRelatedWork W2154590531 @default.
- W1985790489 hasRelatedWork W2158617668 @default.
- W1985790489 hasRelatedWork W2315175766 @default.
- W1985790489 hasRelatedWork W2315201629 @default.
- W1985790489 hasRelatedWork W2325120009 @default.
- W1985790489 hasVolume "7" @default.
- W1985790489 isParatext "false" @default.
- W1985790489 isRetracted "false" @default.
- W1985790489 magId "1985790489" @default.
- W1985790489 workType "article" @default.